FINLATICS

INSIGHT RESEARCH:-4
ABBOTT INDIA LTD

GENERAL OVERVIEW

Since 1910, Abbott has been dedicated to helping

people in India live healthier lives through a diverse
range of science-based nutritional products, diagnostic
tools, branded generic pharmaceuticals, and diabetes
and vascular devices. Headquartered in Mumbai,
Abbott India Limited, a publicly listed company and a
subsidiary of Abbott Laboratories, takes pride in
offering high-quality trusted medicines in multiple
therapeutic categories such as women's health,
gastroenterology, cardiology, metabolic disorders and
primary care.
One of India's fastest-growing pharmaceutical
companies, Abbott India Limited is part of Abbott's
global pharmaceutical business in India. They have
expertise across product development, manufacturing,
sales and customer service and are dedicated to
providing high-quality, reliable products with the
expert clinical support our customers need.
Abbott India Limited believes in providing quality
healthcare through a mix of global and local products
for people in India.

 SHAREHOLDING PATTERN OF ABBOTT INDIA

LTD:-

CATEGORY OF SHARE SHARE HOLDING %

1. PROMOTER & GROUP 74.99%
2. PUBLIC 25.01%
SHAREHOLDING
3.SHARE HELD BY 00.0%
CUSTODIANS

SHAREHOLDING %

25% PROMOTORS & GROUPS

PUBLIC SHAREHOLDING
SHARE HELD BY CUSTODIANS

75%
 MANAGEMENT OF ABBOTT INDIA LTD

NAME DESIGNATION
MUNIR SHAIKH CHAIRMAN (NON
EXECUTIVE)
RAJIV SONALKER WHOLE TIME DIRECTOR
& CFO
SABINA EWING NON EXECUTIVE
OFFICER
KAIYOMARZ MARFATIA NON EXECUTIVE
OFFICER
ANISHA MOTWANI INDEPENDENT
DIRECTOR
VIVEK VASUDEV MANAGING DIRECTOR
KAMATH
KRUPA ANANDPARA COMPANY SECRETARY
SUDARSHAN JAIN INDEPENDENT
DIRECTOR
AMBATI VENU NON EXECUTIVE
OFFICER
SHALINI KAMATH INDEPNDENT DIRECTOR

 BACKGROUND & STABILITY OF ABBOTT INDIA

LTD
The Background page of Abbott India Ltd. captures the
details on Company's Industry, Incorporation Date,
Face Value, Registered Address, Web Site, Registrar,
and Auditors information.

Company Background:-

Industry Name:- Pharma-MNC.

FACE VALUE:- 10.0
ISIN: INE358A01014
House Name:- MNC Associate
Incorporation Date:- 22/8/1944
Market Lot:- 1
Registered address:- 3, corporate park,sion,trombay
road,
City Name:-Mumbai
State:-Maharashtra
Pincode:-400071
Registrar:- KFIN Technologies Pvt. Ltd.
Auditor:-SRBC & Co LLP

STABILITY:-
Abbott India Ltd is one of the largest MNC pharma
companies operating in India. It is a subsidiary of
Abbott Laboratories of USA. Abbott Laboratories held
75% stake in Abbott India. The company is engaged in
the discovery development manufacture and
marketing of pharmaceutical diagnostic nutritional and
hospital products. Abbott India Ltd was originally
incorporated on August 22 1944 as Boots Pure Drug
Company (India) Ltd. The company name was changed
to The Boots Company (India) Ltd on November 1 1971
thereafter to Boots Pharmaceuticals Ltd on January 1
1991. In October 31 1995 the name was changed to
Knoll Pharmaceuticals Ltd and in July 1 2002 they got
their present name Abbott India Ltd. During the
FY2019the company executed 25 new studies
published 45 articles in major indexed journals with 6
international presentations.The company has been
awarded THE MOST INNOVATIVE MNC OF THE YEAR
2019 at the 12th Pharma Leaders Award.During the
FY2020 the company executed 12 new studies
published 16 articles in major indexed journals along
with making four international presentations.During
the FY2021 there was a innovation in Brufen Coating
formula which led to 50% increase in coating Installed
capacity in 2 shifts from 675 mio tabs to 1012 mio tabs
without any capex. Increase in installed capacity will
help site to produce all Brufen SKU's in-house as well
as scope for internalization of new coated
product.During the year 2020-21 the company
executed 8 new studies published 8 articles in major
indexed journals. All the studies were conducted in
compliance with Good Clinical Practice (GCP) and
regulatory requirements.
  SWOT ANALYSIS OF ABBOTT INDIA LTD

 STRENGTH:-
1. Abbott is collaborating with Syngene, India's leading
contract research organization, to establish its first
nutrition research and development (R&D) center in
the country
2. Abbott Molecular has acquired an exclusive license
to develop a diagnostic test in the United States based
on several new biomarkers
3. Includes a broad range of specialized medicines;
medical diagnostic instruments and tests; minimally
invasive surgical devices; a spectrum of nutritional
supplements for infants, children and adults; and
products for veterinary care.
4. Abbott Launches PediaSure SideKicks , a nutritional
beverage to help balance out a picky eater's uneven
diet
5.Strong employee force of 90,000

 WEEKNESS:-
1. Products listed on the site may be available only in
certain countries.
2.Company is overly dependent upon mature products
whose patents may expire in near future
3. Abbot faces lot of litigation cases in various
countries regarding its products

 OPPORTUNITY:-
1. Broad-based medical innovation, in technologies and
businesses   across the spectrum of health care
2. Pioneering solutions that advance health care
3. Address health needs in under-developed and poor
countries
4. Leverage its core business expertise and resources to
create sustainable solutions in countries around the
world.

 THREATS:-
1. Increasing obsolesce of technology
2. Competition from peers

 COMPETITORS OF ABBOTT INDIA LTD

There are several brands in the market which are

competing for the same set of customers. Below are
the top 2 competitors of Aboott india ltd:-

 SUN PHARMA:
 Sun Pharmaceutical Industries Limited (Sun
Pharma) is an
Indian multinational pharmaceutical company
headquartered in Mumbai, Maharashtra, that
manufactures and sells pharmaceutical
formulations and active pharmaceutical
ingredients (APIs) in more than 100 countries across
the globe. It is the largest pharmaceutical company
in India and the fourth largest specialty generic
pharmaceutical company in the world, with a total
revenue of over US$4.5 billion as of June 2021. The

products cater to a vast range of therapeutic

segments covering psychiatry, anti-infectives,
neurology, cardiology, orthopaedic, diabetology,
gastroenterology, ophthalmology, nephrology,
urology, dermatology, gynaecology, respiratory,
oncology, dental and nutritional’s.[4] Its API products
include Absorica, Acamprosate Calcium, Alendronate
Sodium, Amifostine trihydrate, Budensonide and
Carvedilol.

 LUPIN:

Lupin Limited is an
Indian multinational pharmaceutical company based
 in Mumbai, Maharashtra, India. It is one of the
largest generic pharmaceutical companies by
revenue globally.[8] The company's key focus areas
include paediatrics, cardiovascular, anti-infectives,
diabetology, asthma and anti-tuberculosis.

Lupin was founded in 1968 by Desh Bandhu Gupta,

who was a professor of chemistry at BITS-
Pilani, Rajasthan. Gupta moved to Mumbai in the 60s
to work on his business enterprise for which initially
he had initially borrowed Rs 5000 from his wife to
fund his venture. Subsequent funding from Central

Bank Of India, the company was able to start their

manufacturing facility for producing folic acid and
iron tablets for Government of India mother and
child health program. Later Lupin started
manufacturing anti TB drugs which at one point
formed 36% of the company sales and was
considered as the largest TB drugs manufacturer in
the world.

 CONCLUSION:-
On the Study of the SWOT Analysis of Abbott
Laboratories, we know that it is one of the largest
Pharmaceutical Companies in India. It has well-
trained representatives to attend to the customers
and has an opportunity to grow in the international
market which is now developing. Even with such
advantages, it faces some flaws in the market.